Wellspring Financial Advisors LLC Makes New Investment in Cencora, Inc. $COR

Wellspring Financial Advisors LLC acquired a new stake in shares of Cencora, Inc. (NYSE:COR) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,238 shares of the company’s stock, valued at approximately $756,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Cencora by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock valued at $7,976,681,000 after acquiring an additional 221,570 shares during the last quarter. State Street Corp increased its stake in shares of Cencora by 9.3% during the 3rd quarter. State Street Corp now owns 9,190,316 shares of the company’s stock valued at $2,872,249,000 after acquiring an additional 782,911 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Cencora by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock valued at $1,843,268,000 after purchasing an additional 169,055 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Cencora by 6.5% in the 4th quarter. JPMorgan Chase & Co. now owns 4,982,557 shares of the company’s stock valued at $1,682,859,000 after purchasing an additional 304,760 shares in the last quarter. Finally, Boston Partners increased its position in Cencora by 2.0% during the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company’s stock worth $1,409,152,000 after purchasing an additional 89,506 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of COR opened at $281.48 on Thursday. The business’s fifty day moving average price is $290.59 and its 200 day moving average price is $328.55. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The stock has a market capitalization of $54.76 billion, a PE ratio of 21.59, a price-to-earnings-growth ratio of 1.51 and a beta of 0.59. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. During the same quarter last year, the business earned $4.42 earnings per share. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts forecast that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora announced that its Board of Directors has authorized a share repurchase plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 3.9% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Analyst Ratings Changes

A number of research firms recently issued reports on COR. William Blair began coverage on shares of Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating for the company. Evercore set a $360.00 target price on shares of Cencora in a research report on Wednesday, April 8th. Barclays dropped their price target on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research note on Wednesday. Weiss Ratings downgraded shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 22nd. Finally, Leerink Partners reiterated an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Twelve equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $374.00.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.